ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$6.15 USD
-0.46 (-6.96%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $6.15 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
ALX Oncology Holdings Inc. (ALXO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$21.33 | $27.00 | $14.00 | 222.69% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for ALX Oncology Holdings Inc. comes to $21.33. The forecasts range from a low of $14.00 to a high of $27.00. The average price target represents an increase of 222.69% from the last closing price of $6.61.
Analyst Price Targets (6 )
Broker Rating
ALX Oncology Holdings Inc. currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 85.71%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ALXO.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/11/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
6/10/2024 | H.C. Wainwright & Co. | Swayampakula Ramakanth | Strong Buy | Strong Buy |
4/12/2024 | Cantor Fitzgerald & Co | Li Watsek | Strong Buy | Strong Buy |
3/7/2024 | Not Identified | Not Identified | Strong Buy | Hold |
2/9/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Strong Buy |
10/4/2023 | UBS | Colin N Bristow | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 7 |
Average Target Price | $21.33 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.75 |